Onitraz Capsule contains Itraconazole 100mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis, including oropharyngeal and esophageal candidiasis. Onitraz is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. It is metabolized primarily by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, dizziness, and rash. Serious side effects may involve hepatotoxicity and congestive heart failure in susceptible individuals. Due to its potential for drug interactions, particularly with medications metabolized by CYP3A4, careful monitoring and dose adjustments may be required. Onitraz Capsule should be prescribed and used under medical supervision, with consideration of patient history and concomitant therapies to ensure safety and efficacy in the treatment of fungal infections.